HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Revlon Considering Sale Of Businesses After First Quarter Sale Rumors

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

Revlon will explore its "strategic alternatives" in an effort to reduce its approximately $1.66 bil. debt and maximize shareholder value, the company announced April 7.

You may also be interested in...



Revlon Embarks On “Long-Term Prestige Fragrance Strategy”

Revlon plans to launch a prestige scent this summer to kick off a new "long-term prestige fragrance strategy," the mass market cosmetics firm announced Jan. 26

Revlon Embarks On “Long-Term Prestige Fragrance Strategy”

Revlon plans to launch a prestige scent this summer to kick off a new "long-term prestige fragrance strategy," the mass market cosmetics firm announced Jan. 26

Revlon CEO Nugent Aims To Reinvent Brand's Innovative Roots

Revlon President and CEO Jeffrey Nugent plans to rebuild the cosmetics giant by returning to its innovative roots, a heritage that helped make Revlon a world leader in the market.

Table

View full table

Related Content

HBW Insight
Tags:
Latest Headlines

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

See All
UsernamePublicRestriction

Register

RS006545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By